No abstract available
MeSH terms
-
Antibodies, Monoclonal / economics
-
Antimalarials / economics
-
Antineoplastic Agents / economics
-
Antiprotozoal Agents / economics
-
Antitubercular Agents / economics
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins / economics
-
Cholic Acid / economics
-
Chondroitinsulfatases / economics
-
Diarylquinolines / economics
-
Drug Approval / economics*
-
Drug Approval / legislation & jurisprudence
-
Drug Approval / methods
-
Drug Combinations
-
Drug Industry / economics*
-
Drug Industry / legislation & jurisprudence
-
Ethanolamines / economics
-
Fluorenes / economics
-
Humans
-
Neglected Diseases / drug therapy*
-
Phosphorylcholine / analogs & derivatives
-
Phosphorylcholine / economics
-
Program Development / economics*
-
Rare Diseases / drug therapy*
-
United States
-
United States Food and Drug Administration
Substances
-
Antibodies, Monoclonal
-
Antimalarials
-
Antineoplastic Agents
-
Antiprotozoal Agents
-
Antitubercular Agents
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins
-
Diarylquinolines
-
Drug Combinations
-
Ethanolamines
-
Fluorenes
-
Phosphorylcholine
-
miltefosine
-
bedaquiline
-
dinutuximab
-
Chondroitinsulfatases
-
GALNS protein, human
-
Cholic Acid